Acceleron Pharma is focused on developing therapeutics for metabolic and musculoskeletal diseases affecting millions of people. The company was founded with an interesting intellectual property portfolio and a deep knowledge of the largely untapped TGF-beta superfamily. The company has multiple programs in development. Furthermore, the company has created a proprietary discovery and development platform to deepen its pipeline and advance product candidates rapidly and efficiently.

Visit the site

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

Visit the site

Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The Company's powerful research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allows Affimed to identify antibodies against even the most difficult of targets. Affimed's proprietary antibody formats include 'TandAbs™', unique tetravalent antibodies that are particularly well suited to targeting tumor cells.

Visit the site

Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease, epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Visit the site

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.

With more than 500 distinct kinases identified and over 30 kinase inhibitors in clinical trials or FDA approved, this important class of proteins is a rich area for therapeutic drug development.

Ambit's lead compound AC220, a small molecule kinase inhibitor for the treatment of Acute Myeloid Leukemia, entered the clinic in 2006.

Visit the site

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has multiple drug candidates in late-stage clinical trial development.

Visit the site

Aragon Pharmaceuticals is a San Diego-based biopharmaceutical company focused on overcoming hormone-resistant cancers through the creation of a new class of nuclear receptor targeting drugs, thereby opening the door to a pipeline of new anti-endocrine therapies.

Visit the site

arGEN-X is an innovation-driven biopharmaceutical company, transforming the discovery and development of human therapeutic antibodies. Its SIMPLE Antibody™ platform exploits outbred immune responses and gives universal, unbiased target epitope coverage, unravels new disease pathways and creates novel composition of matter intellectual property. This unique capability maximizes antibody lead choice - and together with proprietary half-life extension (NHance™) and enhanced cell killing (Potelligent®) technologies, has enabled arGEN-X to rapidly build an exciting preclinical pipeline of highly differentiated antibody therapeutics.

Visit the site

Focused on immuno-oncology

Visit the site

Arsanis is developing antibody therapeutics for infectious diseases for which current prophylactic or therapeutic approaches are ineffective or nonexistent. Arsanis has access to first-in-class human monoclonal antibody discovery technology that enables the selection of highly potent antibodies with unique biological properties.

Visit the site

Arteaus is a product-focused biotechnology company developing a novel treatment for migraine prevention. Arteaus is developing an antibody to calcitonin gene-related peptide (CGRP) as a novel approach for the prevention of migraine headaches. The world-wide rights to develop the antibody have been licensed from Eli Lilly and Company in an innovative collaboration that leverages Lilly's capabilities and experience developing the antibody with Arteaus' virtual and capital-efficient approach to achieving clinical proof of concept.

Visit the site

Developing gene therapies for orphan muscle diseases

Visit the site

Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions. Industry-leading affinity resin discovery timelines integrate seamlessly into process development cycles, providing improved line-ofsight, platform operations and equipment, and predictable scalability.

Visit the site

Since inception in 1971, BSV has worked ceaselessly to research, develop, manufacture and market specialized biological, pharmaceutical and biotechnology products. Today, BSV is one of the fast growing Indian bio-pharmaceutical companies. The product portfolio comprises of a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums, antifungals, anaesthetics, cardiovascular and diagnostic products.

Visit the site

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.

Visit the site

Visit the site

Bonovo is a leading provider of orthopedic products to the Chinese healthcare market. Bonovo has over 15 years of experience manufacturing and distributing orthopedic products throughout China. Bonovo's unique relationships with leading clinicians and hospitals makes Bonovo an ideal partner for access to the Chinese orthopedic market.

Visit the site

Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary system for Transcatheter Mitral Valve Implantation (TMVI). Through the combination of a unique anchoring mechanism and a novel delivery catheter, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CardiAQ procedure is designed to be performed in a cardiac catheterization laboratory or hybrid operating room. Ultimately, it will be similar to the Transcatheter Aortic Valve Implantation (TAVI) procedure, resulting in less trauma to the patient and substantial potential cost-savings to the healthcare system.

Visit the site

Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.

Visit the site

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.

cCAM has demonstrated proof of concept through in-vivo studies and is entering clinical studies. cCAM will select patients for its clinical studies based on  the fact that CEACAM1 can be measured on tumor cells. This selection may substantially reduce the risks associated with the studies and shorten the clinical path.

Visit the site

Cerapedics is developing and commercializing products for the orthopedic bone substitutes market. The Company's products utilize a proprietary small peptide called P-15™. This peptide has been identified to play an active role in initiating the formation of bone. Cerapedics' products should provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction.

Visit the site

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on breakthrough research in HDL therapy, Cerenis is pursuing a range of HDL product candidates that reflect significant commercial opportunities in the treatment of atherosclerosis. High-density lipoprotein (HDL), also known as "good" cholesterol, is the primary vehicle for removal of excess cholesterol from the body through a process known as "reverse lipid transport." HDL is an important target area for new therapeutic agents to treat cardiovascular disease, which is the leading killer of men and women in industrialized nations

Visit the site

Cleave Biosciences is focused on novel targets in cellular protein homeostasis pathways. Controlled largely by two distinct systems - the ubiquitin proteasome system and the autophagy system, these pathways are utilized by cancer cells for their growth and survival.

Visit the site

Crown Bioscience is a rapidly growing CRO with leadership in translational oncology and cancer drug discovery partnerships, expanding into diabetes and other disease areas with proprietary diabetic monkey models. Leveraging its unique translational oncology assets including HuPrime® and HuKemia® and full in-house drug discovery platforms, the company addresses the critical need of the pharmaceutical industry to improve R&D productivity while minimizing risks and retaining upside.

Visit the site

DFine's mission is to develop and market devices that treat vertebral compression fractures and other spinal disorders in a minimally invasive manner to improve patient quality of life.

DFine's RF Kyphoplasty procedure with the StabiliT® Vertebral Augmentation System is the next generation in kyphoplasty. It combines the benefits of site-specific cavity creation, controlled cement delivery, and potential for height restoration with ultra-high viscosity bone cement. During the procedure, radiofrequency energy is applied to specially formulated energy-responsive bone cement to create an ultra-high viscosity cement. The cement is delivered into a cavity within the vertebra using a remote hand switch that allows the physician to remain up to 10 feet from the fluoroscopic field, potentially reducing the physician's exposure to radiation.

Visit the site

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Visit the site

EA is a medical device company focusing on R&D, manufacture and sales of orthodontics products in China. Since its inception, EA has set the bar for leadership in marketing and commercializing invisible orthodontic products. EA is the largest provider of invisible orthodontic products and services in China.

Visit the site

Ecron Acunova provides services for Phase I-IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab with its research centers in Europe and India. Ecron Acunova provides clinical development services to the pharmaceutical, biotechnology, nutritional, device and medical diagnostics industries. High service quality, wide therapeutic expertise and continuously expanding global reach are central to Ecron Acunova's long lasting commitment.

Visit the site

Eddingpharm is a leading pharmaceuticals marketing company in the fast growing China market. It focuses on in-licensing, marketing and distributing hospital pharmaceutical products.

With over 20 offices and 400 professional sales representatives, Eddingpharm is a partner of choice for many multi-national pharmaceutical companies.

Visit the site

Glaukos Corporation is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management.

Visit the site

Good Start Genetics provides the most clinically relevant genetic information to physicians. The Company's affordable pre-pregnancy test utilizes an advanced DNA sequencing technology to screen for a panel of genetic disorders, including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG). Good Start Genetics' advanced DNA sequencing technology is designed to deliver a higher detection rate and improved clinical performance compared to currently available screening methods, such as genotyping and SNP analysis.

Visit the site

Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. Igenica contends that the key to next generation mAb-based medicines lies in both the identification of new targets and the deployment of novel antibody discovery approaches. To this end, the company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.

Visit the site

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Visit the site

Insulet Corporation is an innovative diabetes management company dedicated to providing superior treatment options and lifelong health benefits to people with diabetes.

Visit the site

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of PBC in patients with an inadequate response to, or who are unable to tolerate, ursodiol (ursodeoxycholic acid), the only approved therapy for this indication. PBC is a chronic autoimmune liver disease that may progress to cirrhosis and liver failure, and it is currently the fifth leading indication for liver transplant in the United States. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma.

Visit the site

Keystone Heart is focused on the development and commercialization of procedural tools and accessories for use during Transcatheter Aortic Valve Implantation (TAVI) and other complex percutaneous structural heart procedures. Keystone is finalizing the development of a novel embolic protection device to shield the brain from emboli during cardiac procedures. The Keystone Heart device is positioned at the aortic arch via a catheter in order to deflect emboli while allowing normal blood flow to the brain. The Keystone Heart device is designed to cover all three cerebral arterial branches off the aorta.

Visit the site

KIMS GCC is a chain of multi-specialty tertiary care hospitals and medical clinics with 100 beds under management focused on delivering high-quality medical care. The group currently manages a network of 6 healthcare delivery facilities in Bahrain, Oman, Saudi Arabia, Qatar and UAE.

Visit the site

KIMS India is a chain of multi-specialty tertiary care hospitals with 600 beds under management focused on delivering high-quality medical care. The group currently manages a network of 4 healthcare delivery facilities across India.

Visit the site

MacroGenics, Inc. is focused on the development of improved immunotherapeutic products, including monoclonal antibodies and vaccines and has identified new targets for the treatment of cancer and inflammatory disorders and the prevention of infectious diseases. The company has an important strategic partnership with Genzyme.

Visit the site

Medigus is a medical device company specializing in developing innovative endoscopic procedures and devices, including the revolutionary disposable endoscope for the treatment of GERD (Gastroesophageal Reflux Disease).

The company, which was founded in January 2000, is based in Israel and is publicly traded on the TASE. Medigus owns a unique and outstanding technological platform enabling the company to bring into the world state-of-the-art medical device products.

Visit the site

MethylGene Inc. (TSX:MYG) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for cancer. The Company's product candidates include:

• MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF1, VEGF2, VEGF3, Ron and Tie-2 receptor tyrosine kinases (Phase 2)
• MGCD290, a fungal Hos2 inhibitor used in combination with azoles for fungal infections (Phase 1)
• Mocetinostat (MGCD0103), an oral, isotype-selective histone deacetylase inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies (Phase 2)

MethylGene's development and commercialization partners include Taiho Pharmaceutical, Otsuka Pharmaceutical and EnVivo Pharmaceuticals.

Visit the site

NxStage Medical is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.

Visit the site

Ornim, Inc., through its fully owned subsidiary Ornim Medical Ltd., is bringing to market the CerOx™ monitor, both FDA-cleared and CE marked device that, using near infrared light and ultrasound waves, continuously, non-invasively and in tandem, monitors two critical parameters in adult patients: regional hemoglobin oxygen saturation in the brain or in regions of skeletal muscle tissue beneath the sensor and microcirculation blood flow in tissue. It is the only solution that offers measurement of this combination. Ornim anticipates that the combined measurement of oxygen saturation and blood flow will become essential during every medical procedure done under general anesthesia, for monitoring brain-injured patients, and during resuscitation. The CerOx monitor is designed for use in a variety of clinical settings including the operating room and the intensive care unit.

Visit the site

Otic Pharma Ltd is developing treatments for diseases of the ear. The company's treatments are based on foam, called "Foam-Otic", rather than drops. Foam-delivery is better than drops, because foams stay in place longer, improving the efficiency of the active pharmaceutical ingredient, such as an antibiotic or steroid, enabling lower and less frequent doses.

Visit the site

OxOnc Development LP is an oncology development company founded by pharmaceutical development executives and oncology experts. OxOnc partners have extensive experience in building and managing oncology research networks in Europe and Asia and in managing global contract research organizations to optimally design and execute clinical trials.

Visit the site

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam® delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles.

The Company is developing DepoBupivacaine™ in clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners.

Visit the site

PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. Our mission is to develop a first-in-class and best-in-class mAb for those target diseases.

Visit the site

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Anticalins® are engineered binding proteins derived from the scaffold of natural human lipocalins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Visit the site

Principia is a privately held biopharmaceutical company focused on the design and development of reversible covalent small molecule drugs. The company is the dominant developer of reversible covalent therapeutics. Principia is creating a pipeline of differentiated drug candidates that offer superior safety and efficacy compared with other technologies. The company is leveraging its reversible covalent platform to build a pipeline of internal drug candidates and to establish partnerships with leading biopharmaceutical companies. Principia's platform is also being used to develop unique research tools to explore new biology, validate new disease targets, and serve as the source of its future pipeline.

Visit the site

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Visit the site

RDD Pharma is a drug-device company that developed an intra-anal drug delivery device that delivers a drug to the anal canal in a controlled manner.

The company utilizes a high-reward low-risk business model by repurposing drugs; By choosing medications that are already approved for other indications and combining them into our proprietary drug-delivery technology, RDD benefits from short regulatory route while maintaining our patent protection.

Visit the site

Realton Corporation is developing powerful and cost effective laser systems for use in the treatment of benign prostatic hyperplasia (BPH), a condition commonly known as enlarged prostate. Realton's surgical laser system and fiber optic delivery device are affordable to developing country hospitals and patients. Realton Corporation is headquartered and has manufacturing facilities in Beijing, and a subsidiary in Suzhou, China.

Visit the site

Receptos is a privately-held drug discovery and development company which utilizes pioneering G-protein coupled receptor (GPCR) technology to facilitate structure-based drug design for developing best-in-class drugs.

Visit the site

Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non- absorbed potassium binder for the treatment of hyperkalemia. Relypsa is dedicated to the discovery of additional product candidates through use of its proprietary polymer platform.

Visit the site

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens.  The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Visit the site

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use.

Visit the site

Roka Bioscience is a privately held company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets. The company's scientific platform is based on proven, proprietary technologies used widely in clinical diagnostic testing and now being introduced into food safety and other industrial markets. Roka's current product line provides food safety professionals with a fully automated molecular pathogen detection solution that delivers rapid, accurate results and improved laboratory efficiencies.

Visit the site

Selecta is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. These synthetic vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information for highly-effective targeting to immune cells to produce an optimal immune response. Selecta's novel synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

Visit the site

Shasun Pharmaceuticals Limited (Shasun), is a UK and India based contract research and manufacturing services company engaged in the manufacture and supply of Active Pharmaceutical Ingredients (API) and formulations to leading global pharmaceutical companies. The company has four API and formulation facilities, all of which are USFDA approved.

Visit the site

Sientra is a medical device company focused on developing and marketing a broad portfolio of products aimed at the fast growing plastic surgery and aesthetics market.

Visit the site

Singulex's technology has been developed into the Erenna™ Immunoassay System, which addresses unmet needs in biomarker discovery and validation. The Erenna System can detect as few as two hundred molecules, which meets or exceeds the detection limits of quantitative real-time PCR. Combining the Erenna System's nanotechnology with tried and proven high-throughput immunoassay micro-technology, Singulex has developed protein assays that are 100-1,000 times more sensitive and use 20-100 fold less sample. This enables detailed industrial-scale analysis of precious clinical specimen repositories, cell culture preparations, and other biological specimens that otherwise cannot be studied.

Visit the site

 Founded in 2006 as Dentatek Corporation by life science-focused accelerator Fjord Ventures, LLC, Sonendo is a privately-held pre-revenue stage company developing innovative technologies to transform endodontic therapy. Sonendo has a new disruptive technology that promises to transform the way root canal therapy (endodontics) is performed. As opposed to current endodontic files that only touch 30-70% of the canal surface, Sonendo's Multisonic Ultracleaning™ technology reaches and cleans everywhere within the canal. In-vitro and in-vivo clinical studies show that Sonendo cleans faster, easier, and better than current available endodontic materials and devices.

Visit the site

Supernus Pharmaceuticals, Inc. (formerly Shire Laboratories) is a specialty pharmaceuticals company that has a broad portfolio of proven and patented drug delivery technologies. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization, Microtrol®, Solutrol® and EnSoTrol®, its oral controlled release technologies, and AvertSM, its reduced abuse potential technology. Supernus is focused on developing differentiated products for targeted specialty therapeutic areas on its own and in partnership with other pharmaceutical companies.

Visit the site

Developing novel biologic mesh implant products

Visit the site

Treato Ltd. provides social health patient intelligence solutions. Its patient intelligence platform offers both patients and healthcare stakeholders unique insights based on the aggregated wisdom of the crowd through its free patient site, treato.com, and its professional service offering, Treato Pharma.

Visit the site

ViewRay's technology, the Renaissance™ System 1000, promises to be the world's first radiation therapy device to allow real-time MRI simultaneous with beam-on radiation delivery. This will enable the healthcare professional to know and do what was previously impossible: to understand where the dose actually went in the patient on any given on-couch radiation therapy session, and to gate the beam in real-time based on the actual anatomy of the patient.

Visit the site

Whale Imaging focuses on the R&D, manufacturing, and marketing of high-tech medical imaging devices which utilizes the company's unique core competencies that combine lowest cost manufacture with high level management experience. We combine low-cost R&D and manufacturing with a highly-skilled and experienced management and workforce to produce high quality and optimal value for our customers, above average returns for our stakeholders, and opportunity for our employees.

Our aim is to be the leader in producing affordable world-class medical imaging systems to our global customers by leveraging our proven proprietary disruptive technology, management expertise, and low-cost manufacturing capabilities in China.

Visit the site